Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ISOPTIN vs AFEDITAB CR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Verapamil inhibits calcium ion influx across cardiac and vascular smooth muscle cells, blocking L-type calcium channels, leading to vasodilation and reduced myocardial contractility and conduction velocity.
Nifedipine is a dihydropyridine calcium channel blocker that inhibits the influx of calcium ions through L-type channels in vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced myocardial contractility.
Treatment of hypertension,Management of angina pectoris,Control of supraventricular tachyarrhythmias (e.g., atrial fibrillation, atrial flutter, PSVT),Off-label: Cluster headache prophylaxis, prevention of migraine, bipolar disorder (manic episodes),Off-label: Hypertrophic cardiomyopathy (obstructive)
Hypertension,Chronic stable angina,Vasospastic angina (Prinzmetal's angina)
Initial dose: 80-120 mg orally three times daily; sustained-release: 120-240 mg orally once daily. IV: 5-10 mg slow IV push over 2 minutes, may repeat after 15-30 minutes. Maximum daily oral dose: 480 mg.
30-60 mg orally once daily, extended-release; maximum 90 mg/day.
Terminal elimination half-life: 4.5-12 hours (mean 8 hours); increases with hepatic impairment or cirrhosis
Terminal elimination half-life is 6-11 hours; prolonged in hepatic impairment and elderly due to reduced clearance
Extensively metabolized in the liver via CYP3A4, CYP3A5, and CYP1A2 isoenzymes; major metabolite is norverapamil (active).
Primarily hepatic via CYP3A4; undergoes extensive first-pass metabolism.
Renal (70% as metabolites, 3-5% unchanged); biliary/fecal (25%)
Renal (80% as inactive metabolites), fecal (15% as metabolites), unchanged drug (<1%)
90% bound to albumin
92-98% bound to plasma proteins (primarily albumin)
4.5 L/kg (extensive tissue distribution, reflects high myocardial and vascular binding)
0.5-0.9 L/kg; high distribution indicates extensive tissue binding
Oral: 20-35% (extensive first-pass hepatic metabolism)
Oral extended-release: approximately 50-60% due to first-pass metabolism; absolute bioavailability is 45-60%
For Cr Cl <30 m L/min: Reduce dose by 50-75% of normal. For Cr Cl 30-50 m L/min: Start at lower end of dosing range. No specific guidelines for dialysis.
No adjustment required for any degree of renal impairment, but use with caution in patients with severe renal failure due to risk of hypotension.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50% and monitor. Child-Pugh C: Use with caution, reduce dose by 70-80%.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
Oral: 4-8 mg/kg/day in 3-4 divided doses; maximum 360 mg/day. IV: 0.1-0.3 mg/kg/dose (max 5 mg) over 2 minutes, repeat after 30 minutes if needed.
Not recommended for use in pediatric patients; safety and efficacy not established.
Start at lower end of dosing range (e.g., 40 mg orally three times daily); titrate slowly due to increased sensitivity and decreased clearance. Monitor for hypotension and bradycardia.
Initiate at lower end of dosing range (30 mg once daily) due to increased sensitivity to hypotensive effects and potential for reduced hepatic clearance.
No FDA black box warning.
No FDA black box warning.
Heart failure: May worsen or precipitate heart failure due to negative inotropic effects.,Hypotension: Can cause symptomatic hypotension.,Conduction abnormalities: May worsen AV block, sinus node dysfunction (risk of bradycardia).,Hepatic impairment: Reduced clearance requires dose adjustment.,Concomitant beta-blockers: Additive negative inotropic and bradycardic effects.,Digoxin: Increases digoxin levels; monitor toxicity.,Neuromuscular disorders: May exacerbate myasthenia gravis or Duchenne muscular dystrophy.,Lactation: Excreted in breast milk; caution advised.
Hypotension, especially with immediate-release formulations,Peripheral edema,Hepatic impairment,Increased angina/acute MI upon withdrawal or dose escalation,Beta-blocker withdrawal,Congestive heart failure
Severe left ventricular dysfunction (ejection fraction <30%) or cardiogenic shock,Hypersensitivity to verapamil or any component of the formulation,Sick sinus syndrome or second/third-degree AV block (except with functioning pacemaker),Atrial flutter or fibrillation with accessory bypass tract (e.g., WPW syndrome) unless ventricular preexcitation is excluded,Concomitant use of IV beta-blockers (within a few hours),Severe hypotension (systolic <90 mm Hg)
Hypersensitivity to nifedipine or any component,Cardiogenic shock,Concomitant use with strong CYP3A4 inducers (e.g., rifampin),Kock pouch (ileostomy)
Grapefruit and grapefruit juice increase verapamil levels, increasing risk of toxicity. Avoid concurrent consumption. Alcohol may exacerbate hypotension and dizziness.
Grapefruit juice increases nifedipine levels via CYP3A4 inhibition; avoid consumption. High-fat meals may delay absorption but do not alter overall exposure. Avoid alcohol as it can exacerbate vasodilation and hypotension.
INSUFFICIENT DATA IN HUMANS: Animal studies show no teratogenic effects at clinically relevant doses. First trimester: case reports not indicating major malformations but risk cannot be excluded. Second/third trimester: may cause fetal bradycardia, hypotension, and intrauterine growth restriction due to placental hypoperfusion; avoid use near term due to risk of uterine atony.
Teratogenic effects not established; first trimester: no data in humans, animal studies show no teratogenicity; second and third trimesters: risk of fetal hypoxia, intrauterine growth restriction (IUGR), and oligohydramnios; may cause neonatal hypotension, bradycardia, and hypoglycemia if used near term. Contraindicated in pregnancy for hypertension; use only if benefit outweighs risk (e.g., tocolysis).
Verapamil (ISOPTIN) is excreted into human breast milk with a milk-to-plasma ratio of approximately 0.6. Limited data suggest low infant doses (estimated 0.1-1% of maternal weight-adjusted dose); caution advised, especially in preterm or ill infants.
Nifedipine excreted into breast milk; M/P ratio approximately 0.42-0.77; limited human data; no adverse effects reported in infants; use with caution during breastfeeding.
Pharmacokinetic changes in pregnancy (increased volume of distribution, enhanced clearance) may require dose titration; no specific recommended dose adjustment, but clinical efficacy and toxicity should guide dosing; consider starting at lower doses and titrating to effect.
Plasma clearance may increase due to higher volume of distribution and metabolism; no specific dose adjustment recommended; titrate based on maternal blood pressure and response; avoid around labor due to tocolytic effect.
IV verapamil (Isoptin) can cause hypotension and bradycardia; have calcium gluconate at bedside to reverse. Avoid in patients with pre-existing heart block or systolic heart failure. Use ECG monitoring during IV administration. In atrial fibrillation, may convert to sinus rhythm but risk of ventricular preexcitation with WPW syndrome.
AFEDITAB CR is a controlled-release formulation of nifedipine, a dihydropyridine calcium channel blocker. Avoid grapefruit juice as it inhibits CYP3A4 metabolism, increasing nifedipine levels. Use cautiously in patients with aortic stenosis or left ventricular dysfunction due to risk of hypotension. Do not crush or chew tablets; intact shell may appear in stool.
Do not stop taking suddenly; may cause chest pain or irregular heartbeat.,Avoid grapefruit and grapefruit juice while taking this medication.,Do not drink alcohol; may increase dizziness and drops in blood pressure.,Take with food or milk if stomach upset occurs.,Report slow or irregular heartbeat, shortness of breath, or swelling of ankles.
Swallow the tablet whole; do not crush, chew, or break it.,Avoid grapefruit juice while taking this medication.,Do not discontinue abruptly; taper under medical supervision.,Report symptoms of hypotension like dizziness or fainting.,Limit alcohol intake as it may worsen side effects.,Monitor for fluid retention (ankle swelling) and notify doctor if worsening.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ISOPTIN vs AFEDITAB CR, answered by our medical review team.
ISOPTIN is a Calcium Channel Blocker that works by Verapamil inhibits calcium ion influx across cardiac and vascular smooth muscle cells, blocking L-type calcium channels, leading to vasodilation and reduced myocardial contractility and conduction velocity.. AFEDITAB CR is a Calcium Channel Blocker that works by Nifedipine is a dihydropyridine calcium channel blocker that inhibits the influx of calcium ions through L-type channels in vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced myocardial contractility.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ISOPTIN and AFEDITAB CR depend on the specific clinical indication. These are both Calcium Channel Blocker agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ISOPTIN is: Initial dose: 80-120 mg orally three times daily; sustained-release: 120-240 mg orally once daily. IV: 5-10 mg slow IV push over 2 minutes, may repeat after 15-30 minutes. Maximum daily oral dose: 480 mg.. The standard adult dose of AFEDITAB CR is: 30-60 mg orally once daily, extended-release; maximum 90 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ISOPTIN and AFEDITAB CR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ISOPTIN is classified as Category C. INSUFFICIENT DATA IN HUMANS: Animal studies show no teratogenic effects at clinically relevant doses. First trimester: case reports not indicating major malformations but risk cann. AFEDITAB CR is classified as Category C. Teratogenic effects not established; first trimester: no data in humans, animal studies show no teratogenicity; second and third trimesters: risk of fetal hypoxia, intrauterine gro. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.